WO2000025727A3 - Use of flumethasone, fluocinolone acetonide fluoromethasone for manufacture of a medicament for the treatment of tumours - Google Patents

Use of flumethasone, fluocinolone acetonide fluoromethasone for manufacture of a medicament for the treatment of tumours Download PDF

Info

Publication number
WO2000025727A3
WO2000025727A3 PCT/US1999/025910 US9925910W WO0025727A3 WO 2000025727 A3 WO2000025727 A3 WO 2000025727A3 US 9925910 W US9925910 W US 9925910W WO 0025727 A3 WO0025727 A3 WO 0025727A3
Authority
WO
WIPO (PCT)
Prior art keywords
flumethasone
medicament
manufacture
fluoromethasone
tumours
Prior art date
Application number
PCT/US1999/025910
Other languages
French (fr)
Other versions
WO2000025727A2 (en
Inventor
Craig P Webb
Curtis D Hose
Anne Monks
Woude George F Vande
Michael E Jeffers
Original Assignee
Us Health
Craig P Webb
Curtis D Hose
Anne Monks
Woude George F Vande
Michael E Jeffers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Craig P Webb, Curtis D Hose, Anne Monks, Woude George F Vande, Michael E Jeffers filed Critical Us Health
Priority to AU14654/00A priority Critical patent/AU1465400A/en
Publication of WO2000025727A2 publication Critical patent/WO2000025727A2/en
Publication of WO2000025727A3 publication Critical patent/WO2000025727A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides the use of flumethasone, flucinolone acetonide, fluorometholone or fluorometholone acetate for the manufacture of a medicament for inhibiting a hepatocyte growth/scatter factor (HGF-SF) induced phenotype in a cell. The present invention also provides methods of inhibiting a hepatocyte growth factor induced cellular phenotype in a subject by administering flumethasone, flucinolone acetonide, fluorometholone or fluorometholone acetate to the subject.
PCT/US1999/025910 1998-11-04 1999-11-03 Use of flumethasone, fluocinolone acetonide fluoromethasone for manufacture of a medicament for the treatment of tumours WO2000025727A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU14654/00A AU1465400A (en) 1998-11-04 1999-11-03 Identification of inhibitors of the hgf-met-upa-plasmin network using a novel cellular assay

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10694498P 1998-11-04 1998-11-04
US60/106,944 1998-11-04
US13061399P 1999-04-22 1999-04-22
US60/130,613 1999-04-22

Publications (2)

Publication Number Publication Date
WO2000025727A2 WO2000025727A2 (en) 2000-05-11
WO2000025727A3 true WO2000025727A3 (en) 2000-09-28

Family

ID=26804213

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/025910 WO2000025727A2 (en) 1998-11-04 1999-11-03 Use of flumethasone, fluocinolone acetonide fluoromethasone for manufacture of a medicament for the treatment of tumours

Country Status (2)

Country Link
AU (1) AU1465400A (en)
WO (1) WO2000025727A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006909A2 (en) * 1992-09-18 1994-03-31 United States Of America, As Represented By The Secretary, Department Of Health And Human Services A method of preventing tumor metastasis
WO1995018621A1 (en) * 1994-01-04 1995-07-13 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
WO1994006909A2 (en) * 1992-09-18 1994-03-31 United States Of America, As Represented By The Secretary, Department Of Health And Human Services A method of preventing tumor metastasis
WO1995018621A1 (en) * 1994-01-04 1995-07-13 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOONE C.W. ET AL: "Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human critical trials: A review.", CANCER RESEARCH, (1990) 50/1 (2-9)., XP000920676 *
DIGIOVANNI J. ET AL: "Inhibition of tumor growth and progression.", CANCER BULLETIN, (1995) 47/6 (464-472)., XP000920658 *
MOERTEL C.G. ET AL: "Phase II trials in the malignant carcinoid tumor and the carcinoid syndrome.", PROCEEDINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, (1982) VOL. 1/- (C-657). CODEN: PMAODO, XP000920650 *

Also Published As

Publication number Publication date
AU1465400A (en) 2000-05-22
WO2000025727A2 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
WO2001091728A3 (en) Nanoemulsion formulations
WO2004091375A3 (en) Epha2 and non-neoplastic hyperproliferative cell disorders
WO2006083779A3 (en) Pharmaceutical composition comprising hydroxylated nebivolol
UA86063C2 (en) Liposomes useful for drug delivery
IL151628A0 (en) Combination therapies with vascular damaging activity
WO2007068354A8 (en) Means and methods for the treatment of tumorous diseases
TW200637565A (en) Use of a sterically hindered platium coordination compound in combination with a non-platium based anti-cancer agent
WO2007079203A3 (en) Treatment for cutaneous t cell lymphoma
BR9915095A (en) Pharmaceutical composition administered in aerosol
WO2004096224A3 (en) Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
SI1781296T1 (en) Quinazoline derivatives and their use in the treatment of thrombocythemia
WO2007037850A3 (en) Enhanced delivery of cells
AU3386100A (en) Anti-tnfalpha antibodies in therapy of asthma
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
Linley et al. Trauma and personal growth.
WO2005058934A3 (en) Glycosylated steroid derivatives with anti-migratory activity
PT1660115E (en) Pharmaceutical combination of g-csf and plgf useful for blood stem cell
WO2006113889A3 (en) Compositions and methods for modulating interleukin-10
WO2000025727A3 (en) Use of flumethasone, fluocinolone acetonide fluoromethasone for manufacture of a medicament for the treatment of tumours
AU5158000A (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
ZA200605900B (en) Glycosylated steroid derivatives with anti-migratory activity
WO2001024764A3 (en) Cell targeting compositions and methods of using the same
WO2007068487A3 (en) Tumour treatment with treg down-regulating active agents
PL1723234T3 (en) Vglut-specific dsrna compounds

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 14654

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase